Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.Initiate treatment for latent tuberculosis prior to SIMPONI ARIA use. Test patients for latent tuberculosis before SIMPONI ARIA use and during therapy.
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Active tuberculosis, including reactivation of latent tuberculosis.Reported infections with TNF blockers, of which SIMPONI ARIA is a member, include: Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.ĭiscontinue SIMPONI ARIA if a patient develops a serious infection. Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death. WARNING: SERIOUS INFECTIONS and MALIGNANCY
0 kommentar(er)
